Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04118608
Other study ID # 2019/370
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 4, 2019
Est. completion date December 22, 2023

Study information

Verified date January 2024
Source Oslo University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis.


Description:

Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis. The project will give much needed information about incidence, aetiologies and the clinical course of rhabdomyolysis. The main objective will be to study rhabdomyolysis with focus on the development of AKI and how laboratory values can guide treatment, and thus act as basis for guidelines. More knowledge is needed about rhabdomyolysis and long-term kidney injury, and the study will aim to identify a risk population for later kidney injury, thus being able to refer this group to follow-up and prevent further injury. On the other hand, exercise-induced rhabdomyolysis patients are probably hospitalized more than necessary these days, and over-treatment could be prevented if better guidelines were obtained. The possible cardiotoxicity of myoglobin needs further study, and would benefit the patient group but also fill a knowledge gap for the clinicians. Therefore, this project will ideally obtain new knowledge for the health services, potentially improve existing practice and fill important knowledge gaps.


Recruitment information / eligibility

Status Completed
Enrollment 310
Est. completion date December 22, 2023
Est. primary completion date December 22, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility 1. Main study: - Inclusion Criteria: Patients age 18 years and older, with a muscle injury developed before hospitalization and serum CK activity =5000 U/L and/or serum myoglobin concentrations =1000 ng/ml within 72 hours after admission will be included. - Exclusion Criteria: Patients with unknown identity will be excluded. 2. Sub-study on rhabdomyolysis and cardiac enzymes: - Inclusion Criteria: All patients with troponins over 14 ng/L and who otherwise fulfills the inclusion criteria can be included. - Exclusion Criteria: Acute coronary syndrome, heart failure, arrythmia, previous myocarditis, circulatory shock, acute pulmonary embolism, thoracic trauma/heart trauma or CKD before hospitalization.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
Norway Oslo University Hospital, Ullevaal Oslo

Sponsors (4)

Lead Sponsor Collaborator
Oslo University Hospital Diakonhjemmet Hospital, Lovisenberg Diakonale Hospital, University Hospital, Akershus

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of Acute Kidney Injury (AKI) AKI will be defined according to KDIGO 2012 guidelines Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
Secondary Risk stratification based on Myoglobin/Creatinine kinase ratio Risk of AKI (see above) can be predicted based on this ratio Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
Secondary Association between rhabdomyolysis, elevated cardiac enzymes and the effect on myocardium. Increased Troponin T levels and findings on echocardiography with strain and in some cardiac IMR Through hospitalization (average 1 week)
See also
  Status Clinical Trial Phase
Completed NCT03737513 - Exercise-induced Collective Rhabdomyolysis
Completed NCT00241748 - Pharmacoepidemiology and Pharmacogenetics of a Statin Adverse Event N/A
Not yet recruiting NCT02498366 - Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty N/A
Not yet recruiting NCT06429982 - Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols Phase 1
Active, not recruiting NCT06101680 - RhabdomYolyse in Intensive caRe
Withdrawn NCT02896517 - Support for the Rhabdomyolysis in an Emergency Department
Completed NCT01467180 - Myoglobin Removal by High Cut-off CVVHD N/A
Recruiting NCT01022450 - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients N/A
Completed NCT00391911 - Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis Phase 2
Withdrawn NCT02111018 - Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis Phase 2
Completed NCT04913298 - Prospective Study for the Application of Cytosorb® in Critically Ill Patients N/A
Recruiting NCT05146336 - CytOSorb TreatMent Of Critically Ill PatientS Registry
Completed NCT03986736 - Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma
Not yet recruiting NCT02518724 - The Effect of Remote Ischemic Preconditioning on Physical Performance and Exertional Rhabdomyolysis N/A
Completed NCT02671604 - Rhabdomyolysis and Robot-assisted Radical Prostatectomy N/A
Completed NCT00592657 - Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions N/A
Completed NCT06338423 - Use of a Vacuum Mattress During Laparoscopic Sleeve Gastrectomy to Reduce the Concentration of Rhabdomyolysis Markers and Acute Renal Failure N/A
Completed NCT01976936 - Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 Phase 2
Completed NCT01544231 - Plasma Neutrophil Gelatinase Associated Lipocalin Levels During Emergency Management of Rhabdomyolysis N/A
Recruiting NCT00549029 - The Association of Genetic Polymorphisms With Statin-Induced Myopathy. N/A